UROLOGY PRACTICE, cilt.5, sa.1, ss.7-13, 2018 (ESCI)
Introduction: Although evidence supports the use of mitomycin C after transurethral bladder tumor resection in reducing recurrent disease, its adoption has been limited. Examinations of claims data may help in exploring patterns of care and barriers to use. Thus, we analyzed a contemporary population based cohort to determine recent trends in mitomycin C use in community practice urology.